Certificate of Analysis
High Performance Liquid Chromatography
Tesamorelin is a synthetic polypeptide composed of 44 amino acids and analogous to growth hormone-releasing hormone (3). The N-terminus of the compound has been modified compared to growth hormone-releasing hormone (GHRH) which researchers suggest may lead to improved stability (3).
Tesamorelin has been studied for its potential mechanism of action, posited to be similar to growth hormone releasing hormones (GHRH) receptors located at the anterior pituitary gland, possibly leading to increased production and secretion of growth hormones. Growth hormones may act on several cells, including hepatocytes, which may then stimulate the synthesis of insulin-like growth factor-1 (IGF-1) (3).
Analogous to GH, IGF-1 has also been posited to potentially stimulate growth, inhibit programmed cell death, glucose reduction and lipolysis (3). Test models exhibiting lipodystrophy report low levels of GH and IGF-1. Researchers studying the action and potential impact of Tesamorelin, suggest that the peptide may positively influence lipid metabolism.
The N-terminus of the GHRH molecule is altered in Tesamorelin, potentially lending stability to the peptide, and also possibly increasing the compound’s resistance to enzyme deactivation, as compared to natural GHRH (7).
Research and Clinical Studies
Tesamorelin Peptide and Lipodystrophy
In this clinical study (10), two phase III studies were conducted with 806 test subjects over a period of 26 weeks, followed by another 26-week extension. Each of the 806 test subjects had immunodeficiencies. The subjects were divided into two groups, one group with 543 subjects were presented with Tesamorelin and the remaining 263 subjects were presented with a placebo for a period of 26 weeks. After this duration, the Tesamorelin subjects were again randomly divided into 2 groups, in which one group continued Tesamorelin influence and the other half were presented with a placebo, for another period of 26 weeks. At week 26, it was observed by the researchers that there was an apparently significant decrease in visceral adipose tissue level amongst the Tesamorelin subjects, by at least 15.4%. Additionally, the levels of triglycerides and cholesterol were reported significantly decreased as compared to the placebo group.
Tesamorelin Peptide and Immunodeficiency-impacted Fat Fractions
Researchers posit that serious immunodeficiences may induce non-alcoholic fatty liver disease (NAFLD) which in clinical cases is reported in nearly 40% of HIV-positive test models (11). In this study (9), 61 test subjects with HIV and a high hepatic fat fraction (HFF) were selected as test models. These subjects were influenced with Tesamorelin or a placebo for a duration of 12 months. The rate of HFF was monitored at the end of the trial. After 12 months, it was reported by the researchers that 35% of subjects presented with Tesamorelin exhibited an apparent reduction in HFF rate by less than 5% vs. only 4% of subjects receiving placebo exhibited any HFF reduction. There was no reported alteration in the glucose levels.
Tesamorelin Peptide and Cognition
In this clinical study (12), immunodeficient test subjects with mild cognitive impairment were observed. The main intent of this study was to determine the potential action of Tesamorelin on neurological functioning. 100 subjects, aged more than 40 years, participated in this trial and underwent Tesamorelin presentation daily for a period of 6 months, followed by all absence of Tesamorelin influence for the next 6 months, and then Tesamorelin was re-introduced once a day for another 6 months. The primary outcome of this study was reported in changes in neurocognitive performance measured by the Global Deficit Score (GDS) after the period of 6 and 12 months. This study is underway and final results are yet to be posted.
Tesamorelin Peptide and Insulin
The main aim of this study (13) was to determine any potential Tesamorelin might exhibit in altering insulin sensitivity. In this clinical trial setting, 53 test subjects with Type II diabetes were observed in this 12-week randomized trial. The subjects were divided into three groups each of which received either a lower or higher concentration of Tesamorelin, or a placebo. Following the study period of 12 weeks, the concentration of fasting glucose, glycosylated hemoglobin and diabetes control was measured. There was no reported significant reduction in either of these parameters. The results of all three groups appeared to be indifferent.
Tesmorelin peptide is available for research and laboratory purposes only. Please review our Terms and Conditions before ordering.
1. Guzman N, Vijayan V. HIV-associated Lipodystrophy. [Updated 2021 May 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK493183/
2. Chemistry review(s), application number: 22-505. Center for Drug evaluation and research. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000ChemR.pdf
3. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548730/
4. National Center for Biotechnology Information. “PubChem Compound Summary for CID 16137828, Egrifta” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Egrifta
5. Egrifta FDA Approval History. https://www.drugs.com/history/egrifta.html
6. Bedimo, Roger. “Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.” HIV/AIDS (Auckland, N.Z.) vol. 3 (2011): 69-79. doi:10.2147/HIV.S14561. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218714/
7. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):49-58. doi: 10.1111/j.1742-7843.2007.00008.x. PMID: 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/
8. Tesamorelin (Subcutaneous Route). https://www.mayoclinic.org/drugs-supplements/tesamorelin-subcutaneous-route/
9. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., & Grinspoon, S. K. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/
10. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
11. Tesamorelin Effects on Liver Fat and Histology in HIV. https://clinicaltrials.gov/ct2/show/NCT02196831
12. Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons. https://clinicaltrials.gov/ct2/show/record/NCT02572323
13. Clemmons, D. R., Miller, S., & Mamputu, J. C. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one, 12(6), e0179538. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472315/
14. Tesamorelin label and prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
NOTE: These products are intended for laboratory research use only. Tesamorelin for sale is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.